RT Journal Article
SR Electronic
T1 High 3-hydroxybutyrate concentrations in the placenta-produced amniotic fluid in the human uterus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.09.23293873
DO 10.1101/2023.08.09.23293873
A1 Satoh, Takumi
A1 Shibata, Takeo
A1 Takata, Emi
A1 Takakura, Masahiro
A1 Han, Jia
A1 Yamada, Sohsuke
YR 2023
UL http://medrxiv.org/content/early/2023/08/13/2023.08.09.23293873.abstract
AB In this study, we report first high concentrations of a ketone body, 3-hydroxybutyrate (3HB) in the amniotic fluid in humans. Although 3HB concentrations in the maternal blood are approximately 0.1, those in the amniotic fluid are approximately 0.6 mM. High placental 3HB production is potentially key for producing and maintaining high 3HB levels in the amniotic fluid. The rate-limiting enzyme, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), is highly expressed in the cells of the chorionic plate and responsible for 3HB production. Therefore, high HMGCS2 expression maintenance is supposed to be pivotal for maintaining the 3HB supply for the human fetus. Here, we propose that humans display two pathways, an amniotic fluid- and another umbilical vein-mediated, for supplying 3HB to the human fetus. These supply pathways are supposedly essential for human brain development during the late phase of pregnancy.Graphical abstract Human fetuses are supported by 3HB from the amniotic fluid for their brain development.HIGHLIGTS 3-Hydroxybutyrate concentrations are high in the amniotic fluid in the human uterus.The chorionic plate of the placenta highly expresses 3-hydroxy-3-methylglutaryl-CoA synthase 2.Human fetuses may be supplied with 3HB for brain development through the amniotic fluid.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Kanazawa Medical University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are available from the corresponding author on reasonable request.HMGCS23-hydroxy-3-methylglutaryl-CoA synthase 23HB3-hydroxybutyrate